Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Acromegaly Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Acromegaly Overview | 9 | 1 |
| Pipeline Products for Acromegaly Comparative Analysis | 10 | 1 |
| Acromegaly Therapeutics under Development by Companies | 11 | 1 |
| Acromegaly Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Acromegaly Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Acromegaly Products under Development by Companies | 16 | 1 |
| Acromegaly Products under Investigation by Universities/Institutes | 17 | 1 |
| Acromegaly Companies Involved in Therapeutics Development | 18 | 16 |
| Aegis Therapeutics, LLC | 18 | 1 |
| Amryt Pharma plc | 19 | 1 |
| Antisense Therapeutics Limited | 20 | 1 |
| Chiasma, Inc. | 21 | 1 |
| Crinetics Pharmaceuticals, Inc. | 22 | 1 |
| DexTech Medical AB | 23 | 1 |
| Foresee Pharmaceuticals, LLC | 24 | 1 |
| Glide Pharmaceutical Technologies Limited | 25 | 1 |
| Ionis Pharmaceuticals, Inc. | 26 | 1 |
| Ipsen S.A. | 27 | 1 |
| Italfarmaco S.p.A. | 28 | 1 |
| Midatech Pharma Plc | 29 | 1 |
| Novartis AG | 30 | 1 |
| Peptron, Inc. | 31 | 1 |
| Strongbridge Biopharma plc | 32 | 1 |
| Sun Pharma Advanced Research Company Ltd. | 33 | 1 |
| Acromegaly Therapeutics Assessment | 34 | 9 |
| Assessment by Monotherapy Products | 34 | 1 |
| Assessment by Target | 35 | 2 |
| Assessment by Mechanism of Action | 37 | 2 |
| Assessment by Route of Administration | 39 | 2 |
| Assessment by Molecule Type | 41 | 2 |
| Drug Profiles | 43 | 34 |
| AP-102 Drug Profile | 43 | 1 |
| atesidorsen sodium Drug Profile | 44 | 8 |
| COR-005 Drug Profile | 52 | 3 |
| FP-002 Drug Profile | 55 | 1 |
| IONIS-GHRLRx Drug Profile | 56 | 1 |
| ITF-2984 Drug Profile | 57 | 1 |
| L-779976 Drug Profile | 58 | 1 |
| octreotide acetate Drug Profile | 59 | 2 |
| octreotide acetate Drug Profile | 61 | 4 |
| octreotide acetate Drug Profile | 65 | 1 |
| octreotide acetate long acting Drug Profile | 66 | 2 |
| octreotide acetate SR Drug Profile | 68 | 1 |
| octreotide acetate SR Drug Profile | 69 | 1 |
| octreotide SR Drug Profile | 70 | 1 |
| pasireotide ER Drug Profile | 71 | 3 |
| Small Molecules to Activate Somatostatin Receptor Type 4 for Polycystic Kidney Disease, Acromegaly and Neuroendocrine Tumors Drug Profile | 74 | 1 |
| Somadex Drug Profile | 75 | 1 |
| SXN-101959 Drug Profile | 76 | 1 |
| Acromegaly Dormant Projects | 77 | 1 |
| Acromegaly Discontinued Products | 78 | 1 |
| Acromegaly Product Development Milestones | 79 | 11 |
| Featured News &Press Releases | 79 | 1 |
| Jul 27, 2016: Positive Results Achieved from Interim Analysis of ATL1103 Higher Dose Study | 79 | 1 |
| Jul 13, 2016: ATL1103 Patent Update | 80 | 1 |
| Jun 28, 2016: Glide Technologies announces successful clinical proof-of-concept study | 81 | 1 |
| Jun 14, 2016: Chiasma Announces Corporate Restructuring Plan and Provides Regulatory Update Regarding Mycapssa | 82 | 1 |
| Jun 01, 2016: Antisense provides update on ATL1103 clinical trials | 82 | 1 |
| May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology | 83 | 1 |
| May 19, 2016: Glide Technologies Initiates Clinical Proof-of-Concept Study with Novel Octreotide Solid Dose Formulation Delivered via Needle-Free SDI | 84 | 1 |
| May 12, 2016: Orphan Drug designation from FDA for ATL1103 in Acromegaly | 84 | 1 |
| Apr 26, 2016: Midatech Pharma announces positive pharmacokinetic data with Q-Octreotide | 85 | 1 |
| Apr 18, 2016: Chiasma Provides Update Regarding FDA s Complete Response Letter for Mycapssa New Drug Application | 85 | 1 |
| Apr 15, 2016: FDA Issues Complete Response Letter for Mycapssa New Drug Application | 86 | 1 |
| Mar 14, 2016: Chiasma Initiates Phase 3 Trial to Support European Registration of Octreotide Capsules for Patients with Acromegaly | 86 | 1 |
| Nov 03, 2015: Strongbridge Biopharma Announces Data Presentation at the Society for Endocrinology BES 2015 Conference | 87 | 1 |
| Sep 09, 2015: ATL1103 Higher Dose Study-Dosing Commenced | 88 | 1 |
| Aug 17, 2015: Chiasma Announces FDA Acceptance For Filing of New Drug Application for Octreotide Capsules in Acromegaly | 88 | 2 |
| Appendix | 90 | 2 |
| Methodology | 90 | 1 |
| Coverage | 90 | 1 |
| Secondary Research | 90 | 1 |
| Primary Research | 90 | 1 |
| Expert Panel Validation | 90 | 1 |
| Contact Us | 90 | 1 |
| Disclaimer | 91 | 1 |